Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

GIST pipeline

What is next, and who is running it?

The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.

A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.

Include Phase 1
ClassNone selected

14 of 17 programs on this timeline

202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today

Asan Medical Center 1

Registry, Aug 31, 2027

Ascentage Pharma 1

Registry, Mar 31, 2027

Bayer 1

RegorafenibApproved
No dated milestone in 2025 to 2030

Blueprint Medicines 1

AvapritinibApproved
No dated milestone in 2025 to 2030

Centre Leon Berard 1

Registry, Oct 2027

Cogent Biosciences 1

FDA PDUFA target action date (GIST, with sunitinib), Nov 30, 2026

Deciphera Pharmaceuticals 2

RipretinibApproved
Registry, Dec 2027
DCC-3009Phase 1/2
Registry, May 2028

GSK 1

Registry, Mar 10, 2027

Merck 1

BelzutifanPhase 2
Registry, Nov 18, 2032

Ningbo Newbay Technology Development 1

NB003Phase 2/3
Registry, Aug 2028

Novartis 1

ImatinibApproved
No dated milestone in 2025 to 2030

Peking University 1

Registry, Jul 30, 2027

Pfizer 1

SunitinibApproved
No dated milestone in 2025 to 2030